



## Health Systems & Economics Publications

1. Thompson K, Kalkowska D, Badizadegan K. Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative. *Gates Open Research* 2022; 6(5). doi:10.12688/gatesopenres.13524.1. <https://gatesopenresearch.org/articles/6-5/v1>. [version 1; awaiting peer review].
2. Thompson KM, Badizadegan K. Health economic analyses of secondary vaccine effects: a systematic review and policy insights. *Expert Rev Vaccines* 2022; 1-16. doi:10.1080/14760584.2022.2017287. <https://www.tandfonline.com/doi/full/10.1080/14760584.2022.2017287>. Epub 20220112.
3. Kalkowska DA, Thompson KM. Health and economic outcomes associated with polio vaccine policy options: 2019-2029. *Risk Anal* 2021; 41(2): 364-75. doi:10.1111/risa.13664. <https://www.ncbi.nlm.nih.gov/pubmed/33590519>. Epub 2021/02/15.
4. Thompson KM, Kalkowska DA, Badizadegan K. A health economic analysis for oral poliovirus vaccine to prevent COVID-19 in the United States. *Risk Anal* 2021; 41(2): 376-86. doi:10.1111/risa.13614. <https://www.ncbi.nlm.nih.gov/pubmed/33084153>. Epub 2020/10/22.
5. Thompson KM, Kalkowska DA, Badizadegan K. No role for reintroducing OPV into the United States with respect to controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]. *Risk Anal* 2021; 41(2): 389-92. doi:10.1111/risa.13671. <https://www.ncbi.nlm.nih.gov/pubmed/33590518>. Epub 2021/02/17.
6. Thompson KM, Kalkowska DA. An updated economic analysis of the global polio eradication initiative. *Risk Analysis* 2021; 41(2): 393-406. doi:10.1111/risa.13665. <https://pubmed.ncbi.nlm.nih.gov/33590521>. Epub 2021/2/5.
7. Ochalek J, Claxton K, Lomas J, Thompson KM. Valuing health outcomes: developing better defaults based on health opportunity costs. *Expert Rev Pharmacoecon Outcomes Res* 2020; 1-8. doi:10.1080/14737167.2020.1812387. <https://www.ncbi.nlm.nih.gov/pubmed/32954900>. Epub 2020/09/22.
8. Thompson KM, Kalkowska DA. Potential Future Use, Costs, and Value of Poliovirus Vaccines. *Risk Anal* 2020. doi:10.1111/risa.13557. <https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/risa.13557?download=true> Epub 2020/07/10.
9. Badizadegan K, Vanlandingham DM, Hampton W, Thompson KM. Value of biopsy in a cohort of children with high-titer celiac serologies: observation of dynamic policy differences between Europe and North America. *BMC Health Serv Res* 2020; 20(1): 962. doi:10.1186/s12913-020-05815-0. <https://bmchealthservres.biomedcentral.com/track/pdf/10.1186/s12913-020-05815-0>. Epub 2020/10/22.
10. Vanlandingham DM, Hampton W, Thompson KM, Badizadegan K. Modeling pathology workload and complexity to manage risks and improve patient quality and safety. *Risk Anal* 2020; 40(2): 421-34. doi:10.1111/risa.13393. <https://www.ncbi.nlm.nih.gov/pubmed/31476083>. Epub 2019/09/03.
11. Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM. Characterising the costs of the global polio laboratory network: a survey-based analysis. *BMJ Open* 2019; 9(1): e023290. doi:10.1136/bmjopen-2018-023290. <https://www.ncbi.nlm.nih.gov/pubmed/30670511>
12. Badizadegan ND, Greenberg S, Lawrence H, Badizadegan K. Radiofrequency Interference in the Clinical Laboratory. *Am J Clin Pathol* 2019; 151(5): 522-8. doi:10.1093/ajcp/aqy174. <https://www.ncbi.nlm.nih.gov/pubmed/30668626>
13. Ozawa S, Yemeke TT, Thompson KM. Systematic review of the incremental costs of interventions that increase immunization coverage. *Vaccine* 2018; 36(25): 3641-9. doi:10.1016/j.vaccine.2018.05.030. <https://www.ncbi.nlm.nih.gov/pubmed/29754699>
14. Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. *Epidemiol Infect* 2017; 145(2): 217-26. doi:10.1017/S0950268816002302. <https://www.ncbi.nlm.nih.gov/pubmed/27760579>
15. Duintjer Tebbens RJ, Thompson KM. Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. *MDM Policy Pract* 2017; 2(1): 2381468317697002. doi:10.1177/2381468317697002. <https://www.ncbi.nlm.nih.gov/pubmed/30288417>



16. Duintjer Tebbens RJ, Thompson KM. Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers. *Vaccine* 2017; 35(31): 3823-33. doi:10.1016/j.vaccine.2017.05.090. <https://www.ncbi.nlm.nih.gov/pubmed/28606811>
17. Thompson KM, Odahowski CL. Systematic review of health economic analyses of measles and rubella immunization interventions. *Risk Anal* 2016; 36(7): 1297-314. doi:10.1111/risa.12331. <https://www.ncbi.nlm.nih.gov/pubmed/25545778>
18. Thompson KM, Odahowski CL. The costs and valuation of health impacts of measles and rubella risk management policies. *Risk Anal* 2016; 36(7): 1357-82. doi:10.1111/risa.12459. <https://www.ncbi.nlm.nih.gov/pubmed/26249331>
19. Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. *Future Microbiol* 2016; 11: 1549-61. doi:10.2217/fmb-2016-0126. <https://www.ncbi.nlm.nih.gov/pubmed/27831742>
20. Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. *BMC Infect Dis* 2015; 15: 374. doi:10.1186/s12879-015-1113-7. <https://www.ncbi.nlm.nih.gov/pubmed/26381878>
21. Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. *BMC Infect Dis* 2015; 15: 376. doi:10.1186/s12879-015-1116-4. <https://www.ncbi.nlm.nih.gov/pubmed/26382234>
22. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. *BMC Infect Dis* 2015; 15: 389. doi:10.1186/s12879-015-1112-8. <https://www.ncbi.nlm.nih.gov/pubmed/26404632>
23. Berera D, Thompson KM. Medical student knowledge, attitudes, and practices regarding immunization. *J Vaccines Vaccin* 2015; 6(1): 1000268. doi:10.4172/2157-7560.1000268. <https://www.longdom.org/open-access/medical-student-knowledge-attitudes-and-practices-regarding-immunization-2157-7560.1000268.pdf>
24. Thompson KM, Strebel PM, Dabbagh A, Cherian T, Cochi SL. Enabling implementation of the global vaccine action plan: developing investment cases to achieve targets for measles and rubella prevention. *Vaccine* 2013; 31 Suppl 2: B149-56. doi:10.1016/j.vaccine.2012.11.091. <https://www.ncbi.nlm.nih.gov/pubmed/23598476>
25. Hennelly KE, Mannix R, Nigrovic LE, Lee LK, Thompson KM, Monuteaux MC, Proctor M, Schutzman S. Pediatric traumatic brain injury and radiation risks: a clinical decision analysis. *J Pediatr* 2013; 162(2): 392-7. doi:10.1016/j.jpeds.2012.07.018. <https://www.ncbi.nlm.nih.gov/pubmed/22921827>
26. Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. *Expert Rev Vaccines* 2012; 11(4): 449-59. doi:10.1586/erv.11.195. <https://www.ncbi.nlm.nih.gov/pubmed/22551030>
27. Thompson KM. Valuing prevention as the new paradigm in global health: Managing population immunity for vaccine-preventable diseases. *ICU Management* 2012; 12(4): 9-11. <https://healthmanagement.org/c/icu/issuearticle/valuing-prevention-as-the-new-paradigm-in-global-health>
28. Goodson JL, Chu SY, Rota PA, Moss WJ, Featherstone DA, Vijayaraghavan M, Thompson KM, Martin R, Reef S, Strebel PM. Research priorities for global measles and rubella control and eradication. *Vaccine* 2012; 30(32): 4709-16. doi:10.1016/j.vaccine.2012.04.058. <https://www.ncbi.nlm.nih.gov/pubmed/22549089>
29. Thompson KM, Rabinovich R, Conteh L, Emerson CI, Hall BF, Singer PA, Vijayaraghavan M, Walker D. Group report: developing an eradication investment case. In: Cochi SL, Dowdle WR, eds. *Disease Eradication in the 21st Century: Implications for Global Health*. Cambridge, MA: MIT Press; 2011: 133-48.
30. Thompson KM, Duintjer Tebbens RJ. Economic evaluation of the benefits and costs of disease elimination and eradication initiatives. In: Cochi SL, Dowdle WR, eds. *Disease Eradication in the 21st Century: Implications for Global Health*. Cambridge, MA: MIT Press; 2011: 115-30.
31. Badizadegan K, Thompson KM. Value of information in nonfocal colonic biopsies. *J Pediatr Gastroenterol Nutr* 2011; 53(6): 679-83. doi:10.1097/MPG.0b013e31822862d9. <https://www.ncbi.nlm.nih.gov/pubmed/21681109>



33. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, Aylward RB, Thompson KM. Economic analysis of the global polio eradication initiative. *Vaccine* 2010; 29(2): 334-43. doi:10.1016/j.vaccine.2010.10.026. <https://www.ncbi.nlm.nih.gov/pubmed/21029809>
34. Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander J, Jafari H, Cochi SL. The risks, costs, and benefits of possible future global policies for managing polioviruses. *Am J Public Health* 2008; 98(7): 1322-30. doi:10.2105/AJPH.2007.122192. <https://www.ncbi.nlm.nih.gov/pubmed/18511720>
35. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM. Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management. *Risk Anal* 2008; 28(4): 855-76. doi:10.1111/j.1539-6924.2008.01078.x. <https://www.ncbi.nlm.nih.gov/pubmed/18627544>
36. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. *Lancet* 2007; 369(9570): 1363-71. doi:10.1016/S0140-6736(07)60532-7. <https://www.ncbi.nlm.nih.gov/pubmed/17448822>
37. Thompson KM. Eradicating polio: the dollars and sense. *MedGenMed* 2007; 9(4): 11. doi:N/A. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234286/>
38. Thompson KM, Duintjer Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. *Risk Anal* 2006; 26(6): 1423-40. doi:10.1111/j.1539-6924.2006.00831.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184390>
39. Riederer AM, Thompson KM, Fuentes JM, Ford TE. Body weight and water ingestion estimates for women in two communities in the Philippines: the importance of collecting site-specific data. *Int J Hyg Environ Health* 2006; 209(1): 69-80. doi:10.1016/j.ijheh.2005.08.002. <https://www.ncbi.nlm.nih.gov/pubmed/16373204>
40. Duintjer Tebbens RJ, Sangrujee N, Thompson KM. The costs of future polio risk management policies. *Risk Anal* 2006; 26(6): 1507-31. doi:10.1111/j.1539-6924.2006.00842.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184394>
41. Wendler D, Belsky L, Thompson KM, Emanuel EJ. Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit. *JAMA* 2005; 294(7): 826-32. doi:10.1001/jama.294.7.826. <https://www.ncbi.nlm.nih.gov/pubmed/16106008>
42. Yokota F, Thompson KM. Value of information literature analysis: a review of applications in health risk management. *Med Decis Making* 2004; 24(3): 287-98. doi:10.1177/0272989x04263157. <https://www.ncbi.nlm.nih.gov/pubmed/15155018>
43. Williams RA, Thompson KM. Integrated analysis: combining risk and economic assessments while preserving the separation of powers. *Risk Anal* 2004; 24(6): 1613-23. doi:10.1111/j.0272-4332.2004.00554.x. <https://www.ncbi.nlm.nih.gov/pubmed/15660616>
44. Ko G, Thompson KM, Nardell EA. Estimation of tuberculosis risk on a commercial airliner. *Risk Anal* 2004; 24(2): 379-88. doi:10.1111/j.0272-4332.2004.00439.x. <https://www.ncbi.nlm.nih.gov/pubmed/15078308>
45. Thompson KM, Segui-Gomez M, Graham JD. Validating benefit and cost estimates: the case of airbag regulation. *Risk Anal* 2002; 22(4): 803-11. doi:10.1111/0272-4332.00070. <https://www.ncbi.nlm.nih.gov/pubmed/12224752>
46. Marcy TW, Stefanek M, Thompson KM. Genetic testing for lung cancer risk: if physicians can do it, should they? *J Gen Intern Med* 2002; 17(12): 946-51. doi:10.1046/j.1525-1497.2002.20378.x. <https://www.ncbi.nlm.nih.gov/pubmed/12472931>
47. Lieu TA, Thompson KM, Prosser LA, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL. Emerging issues in vaccine economics: perspectives from the USA. *Expert Rev Vaccines* 2002; 1(4): 433-42. doi:10.1586/14760584.1.4.433. <https://www.ncbi.nlm.nih.gov/pubmed/12901581>
48. Ko G, Burge HA, Nardell EA, Thompson KM. Estimation of tuberculosis risk and incidence under upper room ultraviolet germicidal irradiation in a waiting room in a hypothetical scenario. *Risk Anal* 2001; 21(4): 657-73. doi:10.1111/0272-4332.214142. <https://www.ncbi.nlm.nih.gov/pubmed/11726019>
49. Claxton K, Thompson KM. A dynamic programming approach to the efficient design of clinical trials. *J Health Econ* 2001; 20(5): 797-822. doi:10.1016/S0167-6296(01)00093-5. <https://www.ncbi.nlm.nih.gov/pubmed/11558649>



50. Koop CE, Juberg DR, Benedek EP, Brecher RW, Brent RL, Cole P, Corn M, Covello VV, Downes TW, Gad SC, Gold LS, Guengerich FP, Higginson J, Konemann WH, Lamb IJ, Liroy PJ, Lundberg GD, Thompson KM. A scientific evaluation of health effects of two plasticizers used in medical devices and toys: A Report from the American Council on Science and Health. *MedGenMed* 1999: E14.  
<https://www.ncbi.nlm.nih.gov/pubmed/11104416>
51. Graham JD, Thompson KM, Goldie SJ, Segui-Gomez M, Weinstein MC. The cost-effectiveness of air bags by seating position. *JAMA* 1997; 278(17): 1418-25. doi:10.1001/jama.1997.03550170048031.  
<https://www.ncbi.nlm.nih.gov/pubmed/9356000>